BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25047030)

  • 1. A gatekeeper helix determines the substrate specificity of Sjögren-Larsson Syndrome enzyme fatty aldehyde dehydrogenase.
    Keller MA; Zander U; Fuchs JE; Kreutz C; Watschinger K; Mueller T; Golderer G; Liedl KR; Ralser M; Kräutler B; Werner ER; Marquez JA
    Nat Commun; 2014 Jul; 5():4439. PubMed ID: 25047030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty aldehyde dehydrogenase: genomic structure, expression and mutation analysis in Sjögren-Larsson syndrome.
    Rizzo WB; Lin Z; Carney G
    Chem Biol Interact; 2001 Jan; 130-132(1-3):297-307. PubMed ID: 11306053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular basis of Sjögren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene.
    Rizzo WB; Carney G; Lin Z
    Am J Hum Genet; 1999 Dec; 65(6):1547-60. PubMed ID: 10577908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of recombinant human fatty aldehyde dehydrogenase: implications for Sjögren-Larsson syndrome.
    Lloyd MD; Boardman KD; Smith A; van den Brink DM; Wanders RJ; Threadgill MD
    J Enzyme Inhib Med Chem; 2007 Oct; 22(5):584-90. PubMed ID: 18035827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency.
    Rizzo WB
    Mol Genet Metab; 2007 Jan; 90(1):1-9. PubMed ID: 16996289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of fatty aldehyde dehydrogenase deficiency in Sjögren-Larsson syndrome.
    Haug S; Braun-Falco M
    Gene Ther; 2006 Jul; 13(13):1021-6. PubMed ID: 16525484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sjogren-Larsson syndrome associated hypermelanosis.
    Xu YC; Hou JQ; Zhu WJ; Li P
    J Cosmet Dermatol; 2020 Apr; 19(4):789-798. PubMed ID: 31697031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene.
    De Laurenzi V; Rogers GR; Hamrock DJ; Marekov LN; Steinert PM; Compton JG; Markova N; Rizzo WB
    Nat Genet; 1996 Jan; 12(1):52-7. PubMed ID: 8528251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sjögren-Larsson syndrome: diversity of mutations and polymorphisms in the fatty aldehyde dehydrogenase gene (ALDH3A2).
    Rizzo WB; Carney G
    Hum Mutat; 2005 Jul; 26(1):1-10. PubMed ID: 15931689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implications for gene therapy in Sjogren-Larsson syndrome.
    Haug S; Braun-Falco M
    Arch Dermatol Res; 2005 Jun; 296(12):568-72. PubMed ID: 15834613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A common deletion mutation in European patients with Sjögren-Larsson syndrome.
    Rizzo WB; Carney G; De Laurenzi V
    Biochem Mol Med; 1997 Dec; 62(2):178-81. PubMed ID: 9441870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incomplete Sjögren-Larsson syndrome in two Japanese siblings.
    Kawakami T; Saito R; Fujikawa Y; Kazama H; Shinomiya N; Yamaguchi K; Yamaguchi Y; Aoki T; Kobayashi T
    Dermatology; 1999; 198(1):93-6. PubMed ID: 10026413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sjögren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase in cultured fibroblasts.
    Rizzo WB; Craft DA
    J Clin Invest; 1991 Nov; 88(5):1643-8. PubMed ID: 1939650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A missense mutation in the FALDH gene identified in Sjögren-Larsson syndrome patients originating from the northern part of Sweden.
    Sillén A; Jagell S; Wadelius C
    Hum Genet; 1997 Aug; 100(2):201-3. PubMed ID: 9254849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzymatic diagnosis of Sjögren-Larsson syndrome using electrospray ionization mass spectrometry.
    Sanders RJ; Ofman R; Dekker C; Kemp S; Wanders RJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Feb; 877(4):451-5. PubMed ID: 19124283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sjögren-Larsson syndrome due to a novel mutation in the FALDH gene.
    Botelho Gomes JM; Vieira AP; Navarro J; Maré R; Tavares P; Brito C
    Eur J Dermatol; 2011; 21(3):412-3. PubMed ID: 21524986
    [No Abstract]   [Full Text] [Related]  

  • 17. RNA-based mutation screening in German families with Sjögren-Larsson syndrome.
    Kraus C; Braun-Quentin C; Ballhausen WG; Pfeiffer RA
    Eur J Hum Genet; 2000 Apr; 8(4):299-306. PubMed ID: 10854114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype and phenotype variability in Sjögren-Larsson syndrome.
    Weustenfeld M; Eidelpes R; Schmuth M; Rizzo WB; Zschocke J; Keller MA
    Hum Mutat; 2019 Feb; 40(2):177-186. PubMed ID: 30372562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of microsomal fatty aldehyde dehydrogenase in the alpha-oxidation of phytanic acid.
    Verhoeven NM; Jakobs C; Carney G; Somers MP; Wanders RJ; Rizzo WB
    FEBS Lett; 1998 Jun; 429(3):225-8. PubMed ID: 9662422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel ALDH3A2 mutations in structural and functional domains of FALDH causing diverse clinical phenotypes in Sjögren-Larsson syndrome patients.
    Rajeshwari M; Karthi S; Singh R; Efthymiou S; Gowda VK; Varalakshmi P; Srinivasan VM; Houlden H; Keller MA; Rizzo WB; Ashokkumar B
    Hum Mutat; 2021 Aug; 42(8):1015-1029. PubMed ID: 34082469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.